RxDoctor Payments Data

Stella Milos, MD

Family Medicine · Glendale, NYNPI 1154303147

Payments from drug & device makers

$3,379in general payments, 2019–2025

Across 143 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$613
  • Abbott$446
  • GSK$278
  • Johnson & Johnson$249
  • Lilly USA, LLC$241
  • AbbVie$220
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,372100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,379 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$41,189
Medicare patients
81
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$93,796
JardianceEmpagliflozin75$86,476
OzempicSemaglutide64$68,958
FarxigaDapagliflozin Propanediol58$54,160
JanuviaSitagliptin Phosphate60$48,665
EntrestoSacubitril/Valsartan13$21,316
XareltoRivaroxaban33$21,290
TradjentaLinagliptin18$17,081
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$12,700
VascepaIcosapent Ethyl19$12,560
Diclofenac Sodium47$11,180
Bydureon BciseExenatide Microspheres11$8,643
Metformin Hcl300$6,722
SymbicortBudesonide/Formoterol Fumarate28$6,389
Atorvastatin Calcium464$4,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$215$103,55793 claims
PfizerEliquis$152$93,796100 claims
Novo NordiskOzempic$218$68,95864 claims
AstraZenecaFarxiga, Symbicort$613$60,54986 claims
MerckJanuvia$127$48,66560 claims
NovartisEntresto$104$21,31613 claims
Johnson & JohnsonXarelto$249$21,29033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Glendale

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →